Epigenetic dysregulation in the pathogenesis of systemic lupus erythematosus

Y Araki, T Mimura - International Journal of Molecular Sciences, 2024 - mdpi.com
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease in which immune
disorders lead to autoreactive immune responses and cause inflammation and tissue …

Novel and potential future therapeutic options in systemic autoimmune diseases

L Balogh, K Oláh, S Sánta, N Majerhoffer… - Frontiers in …, 2024 - frontiersin.org
Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and
can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a …

Systemic Lupus Erythematosus: A Review

CH Siegel, LR Sammaritano - JAMA, 2024 - jamanetwork.com
Importance Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterized by inflammation and immune-mediated injury to multiple organ systems …

Cerebrospinal Fluid Analysis in Rheumatological Diseases with Neuropsychiatric Complications and Manifestations: A Narrative Review

M Castellazzi, R Candeloro, M Pugliatti, M Govoni… - Diagnostics, 2024 - mdpi.com
The analysis of cerebrospinal fluid (CSF) remains a valuable diagnostic tool in the
evaluation of inflammatory and infectious conditions involving the brain, spinal cord, and …

Managing lupus nephritis in children and adolescents

EY Chan, FF Lai, AL Ma, TM Chan - Pediatric Drugs, 2024 - Springer
Lupus nephritis is an important manifestation of systemic lupus erythematosus, which leads
to chronic kidney disease, kidney failure, and can result in mortality. About 35%–60% of …

Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: A single-center retrospective study

J Kosałka-Węgiel, R Dziedzic, A Siwiec-Koźlik… - Rheumatology …, 2024 - Springer
Background Lupus nephritis (LN) manifests systemic lupus erythematosus (SLE) and is
characterized by various clinical and laboratory features. This study aimed to …

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

SA Jones, EF Morand - Drugs, 2024 - Springer
The development of new medicines for systemic lupus erythematosus (SLE) has not
addressed unmet clinical need, with only three drugs receiving regulatory approval for SLE …

Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

V Golder, R Kandane-Rathnayake, N Li… - The Lancet …, 2024 - thelancet.com
Background Validation of protective associations of the lupus low disease activity state
(LLDAS) against flare, irreversible damage, health-related quality of life, and mortality has …

Interferon autoantibodies as signals of a sick thymus

BE Oftedal, T Sjøgren, ASB Wolff - Frontiers in Immunology, 2024 - frontiersin.org
Type I interferons (IFN-I) are key immune messenger molecules that play an important role
in viral defense. They act as a bridge between microbe sensing, immune function …

Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force

J Blaess, S Geneton, T Goepfert, S Appenzeller… - RMD open, 2024 - rmdopen.bmj.com
Objective This international task force aimed to provide healthcare professionals and
persons living with systemic lupus erythematosus (SLE) with consensus-based …